Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Clinical Trials Evaluating Proton Therapy

View through CrossRef
Although proton therapy was developed almost 80 years ago, widespread clinical implementation has been limited until the past decade. With the growing use of proton therapy, there is a desire to prove the equivalence or superiority of proton therapy across a number of cancer disease sites. Dozens of clinical trials have been developed to accomplish this within individual institutions, among a few centers, and across national and international networks such as the National Cancer Institute’s National Clinical Trial Network. The protocols include proton therapy imbedded in trials with photon therapy as well as randomized photon vs. proton trials. This chapter provides an overview of the design of such trials as well as some of the challenges facing protocols with proton therapy.
Title: Clinical Trials Evaluating Proton Therapy
Description:
Although proton therapy was developed almost 80 years ago, widespread clinical implementation has been limited until the past decade.
With the growing use of proton therapy, there is a desire to prove the equivalence or superiority of proton therapy across a number of cancer disease sites.
Dozens of clinical trials have been developed to accomplish this within individual institutions, among a few centers, and across national and international networks such as the National Cancer Institute’s National Clinical Trial Network.
The protocols include proton therapy imbedded in trials with photon therapy as well as randomized photon vs.
proton trials.
This chapter provides an overview of the design of such trials as well as some of the challenges facing protocols with proton therapy.

Related Results

Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
New frontiers in proton therapy: applications in cancers
New frontiers in proton therapy: applications in cancers
Abstract Proton therapy offers dominant advantages over photon therapy due to the unique depth‐dose characteristics of proton, which can cause a dramatic reductio...
Radiobiology of proton therapy and its clinical implications
Radiobiology of proton therapy and its clinical implications
The chapter delves into the intricate relationship between proton therapy and its impact on biological systems, shaping the landscape of modern cancer treatment. Proton accelerator...
Unraveling the mechanism of proton translocation in the extracellular half-channel of bacteriorhodopsin
Unraveling the mechanism of proton translocation in the extracellular half-channel of bacteriorhodopsin
AbstractBacteriorhodopsin, a light activated protein that creates a proton gradient in halobacteria, has long served as a simple model of proton pumps. Within bacteriorhodopsin, se...
List-mode proton CT reconstruction
List-mode proton CT reconstruction
Reconstruction tomographique proton CT en mode liste La thérapie proton est utilisée dans le cadre du traitement contre le cancer afin de parvenir à une meilleure d...
Ground state quantum vortex proton model
Ground state quantum vortex proton model
Abstract A novel photon-based proton model is developed. A proton’s ground state is assumed to be coherent to the degree that all of its mass-energy precipitates into a sin...

Back to Top